AO-022 is a potent conformational inhibitor of TALDO1. It reduces the protein expression of vimentin and snail, exhibiting antiproliferative and antitumor activities. AO-022 holds potential for use in breast cancer research.

AO-022 inhibits cell viability in MDA-MB-231 cells in a dose-dependent manner at concentrations of 5, 10, 20, 40, and 80 µM over 24 hours. Additionally, AO-022 reduces the protein expression of vimentin and snail in a dose-dependent fashion at concentrations of 0, 2.5, 5, 10, and 20 µM after 24 hours.

AO-022, administered intraperitoneally at a dosage of 50 mg/kg every other day over a fourteen-day period, demonstrated antitumor activity in mice.